|Synonyms||anti-TRAIL receptor 2 monoclonal antibody, AMG-655|
|Chemical and physical data|
|Molar mass||145.65 kg/mol|
|(what is this?)|
Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.
- Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
- National Cancer Institute: Definition of conatumomab
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|